FOR IMMEDIATE RELEASE

HUMAN CLINICAL STUDY DEMONSTRATES MAGNESIUM THREONATE (MAGTEIN®) IMPROVES COGNITIVE HEALTH

City of Industry, CA -- March 9, 2016 -- A recent “gold standard” randomized, controlled, double-blind study published in the Journal of Alzheimer’s Disease, one of the country’s most prestigious cognitive health medical journals, concludes that nutritional supplementation with Magnesium Threonate (Magtein®), was effective at reversing cognitive impairment, and returned cognitive function almost back to normal ability relative to age.

Guosong Liu, M.D., Ph.D., a former professor at the Massachusetts Institute of Technology, is Professor and Founding Director of the Center for Learning and Memory, School of Medicine, Tsinghua University, Beijing. He is one of the leading experts in magnesium and cognitive health and the principal investigator on the study. He said, “The loss of cognitive function is one of the greatest health fears of older adults. The Centers for Disease Control and Prevention (CDC) estimates that more than 16 million people live with it.¹ Cognitive impairment adversely affects the quality of our daily lives, from stealing our memories to robbing us of basic daily physical activity.”

Dr Liu added, “The current study also demonstrates the safety and efficacy of Magnesium Threonate (Magtein®), a compound designed to help magnesium to cross the blood brain barrier so that it can increase brain synapse density on restoration of certain cognitive abilities. This study highlights the importance of increasing neuronal intracellular magnesium, a key intermediary of synapse density control, for improving cognitive abilities in older adults.”
The effect of Magnesium Threonate (Magtein®) on cognitive ability was evaluated in four cognitive domains: executive function, working memory, attention, and episodic memory by administration of the Trail Making, Digit Span, Flanker, and Face-Name tests, respectively, at Baseline, Week 6, and Week 12. These cognitive tests represent the best science available, based on the current consensus that multiple domains of cognition should be evaluated to determine cognitive impairment. The cognitive domains we selected were similar to those included in major cognitive studies. They are considered reliable for testing cognitive deficits and improvements.

Following 12 weeks of Magnesium Threonate (Magtein®) use there was an average increase of 10.3±3.8% in TMT-B speed, such that their speed was close to that of their age-matched controls. The data demonstrates that Magnesium Threonate (Magtein®) use was effective in subjects at improving cognitive ability almost back to normal levels relative to age.

Subject population included forty-four men or women between 50 and 70 years of age with self-reported memory loss and sleep disorder. The mean subject age was 57.3±5.2 years, with 71% being female.

Magnesium Threonate (Magtein®) is available as dietary supplement and hold multiple patents. AIDP supplied the Magnesium Threonate (Magtein®) for this study.

# # #
AIDP is a leader in the supply of functional ingredients, with a focus on extensively researched products that meet consumer demand for wellness and healthy aging. Our commitment is to source high-quality ingredients and to provide proprietary solutions that address formulation challenges. AIDP’s success is grounded in its depth of experience and commitment to strong science for functional food and beverage product development.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

---